Receiver operator characteristics curve for the optimal response classifiers, optimized for maximum F1-Score. The AUCs for each classifier are reported in the legend. Image courtesy of Gregory J. Czarnota -[email protected]
August 6, 2021 —Oncotargetpublished "MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer" which reported that the authors investigated whether pre-treatment T2-weightedmagnetic resonance imaging(MRI) can be used to predict response to neoadjuvant chemotherapy inbreast cancer.
Response assessment was done using clinical-pathological responses with patients classified into binary groups: responders and non-responders.
Sevent features were significantly different between the two response groups. The best classification accuracy was obtained using a k-nearest neighbor model with sensitivity, specificity, accuracy, and area under curve of 63, 93, 87, and 0.78, respectively.
Pre-treatment T2-weighted MRI texture features can predict NAC response with reasonable accuracy.
Gregory J. Czarnota, M.D., fromThe Sunnybrook Health Sciences Centre,The University of Torontoas well asRyerson Universitysaid, "Locally advanced breast cancer (LABC) is defined as breast cancer with tumors greater than 5 cm, primary disease involving the chest wall, skin, or advanced regional lymph node metastasis, without distant metastases."
病理缓解率较差，约20-40%的患者达到病理完全缓解。在选定的耐药患者队列中，开发影像学生物标志物有助于识别可能受益于NAC的患者，避免无效治疗。
Radiomic analysis involving a wide range of imaging modalities, including magnetic resonance imaging, quantitative ultrasound, and computed tomography, has shown promising results in the assessment of clinical outcomes for patients with breast cancer.
In T2-weighted breast MRI, the texture of these images has been significantly correlated with pathological heterogeneity such that the texture could hypothetically be used to predict patient prognosis. The study examined T2 non-contrast images in predicting the treatment response to NAC.
The Czarnota Research Team concluded in theirOncotarget Research Output当前研究的一个限制是使用不同的化疗方案。其他的纹理特征可以通过替代方法从肿瘤中提取，如灰色游程矩阵、灰色大小区域矩阵和一阶特征，这些将被纳入未来的后续研究。他们打算扩大目前的研究队列，纳入更多的患者来执行更可靠的验证策略，包括考虑来自不同机构的外部验证。
In comparison to other studies, these authors had used a different endpoint towards detection of chemotherapy response. They believe in clinical practice; it will be more prudent to continue NAC in patients demonstrating some or partial response rather than considering a stricter criterion of complete response.
For more information:www.oncotarget.com
August 12, 2022
